Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-06-20

Last Posted Date: 2011-03-07

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT00024141

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)

Phase 3

Terminated

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2003-06-17

Last Posted Date: 2020-12-02

Lead Sponsor: American College of Radiology Imaging Network

Registration Number: NCT00023868

Locations: 🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

and more 6 locations

Oxaliplatin and Bevacizumab (Avastin™) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

First Posted Date: 2003-06-06

Last Posted Date: 2013-11-06

Lead Sponsor: Prologue Research International

Registration Number: NCT00062426

Locations: 🇺🇸
Physicians East - Quadrangle, Greenville, North Carolina, United States
🇺🇸
Northwestern Connecticut Oncology-Hematology Associates, Torrington, Connecticut, United States
🇺🇸
Jackson Oncology Associates, PLLC, Jackson, Mississippi, United States

and more 49 locations

Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer

Phase 3

Completed

Conditions: Colorectal Cancer

Interventions: Biological: cetuximab
Drug: oxaliplatin
Drug: leucovorin
Drug: 5-fluorouracil

First Posted Date: 2003-06-06

Last Posted Date: 2010-04-12

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 102

Registration Number: NCT00061815

Locations: 🇺🇸
ImClone Investigational Site, Richmond, Virginia, United States

Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer

Phase 3

Completed

Conditions: Stage II Colon Cancer
Stage III Colon Cancer

Interventions: Drug: leucovorin calcium
Drug: fluorouracil
Other: laboratory biomarker analysis
Drug: oxaliplatin

First Posted Date: 2003-05-14

Last Posted Date: 2013-01-14

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2472

Registration Number: NCT00004931

Locations: 🇺🇸
National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania, United States

Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2003-05-08

Last Posted Date: 2013-06-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00004059

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Advanced Cancer of the Mouth, Pharynx, or Larynx

Phase 2

Conditions: Head and Neck Cancer

First Posted Date: 2003-05-08

Last Posted Date: 2014-01-06

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004094

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
Monroe Medical Associates, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States

and more 1 locations

Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Biological: interferon-alfa-2b
Drug: cisplatin
Drug: 5-fluorouracil
Radiation: radiation therapy

First Posted Date: 2003-05-07

Last Posted Date: 2016-12-07

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 89

Registration Number: NCT00059826

Locations: 🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
James Graham Brown Cancer Center at University of Louisville, Louisville, Kentucky, United States

and more 11 locations

Oxaliplatin Combined With Fluorouracil and Leucovorin in Treating Patients With Recurrent or Metastatic Cancer of the Esophagus or Stomach

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer

Interventions: Drug: FOLFOX regimen
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin

First Posted Date: 2003-05-07

Last Posted Date: 2013-02-11

Lead Sponsor: University of Chicago

Target Recruit Count: 35

Registration Number: NCT00004127

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Lutheran General Cancer Care Center, Park Ridge, Illinois, United States

and more 19 locations

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Mucinous Adenocarcinoma of the Rectum
Signet Ring Adenocarcinoma of the Colon
Stage IIIC Rectal Cancer
Mucinous Adenocarcinoma of the Colon
Stage IIIA Colon Cancer
Stage IIIA Rectal Cancer
Recurrent Rectal Cancer
Signet Ring Adenocarcinoma of the Rectum
Stage IIIB Rectal Cancer
Stage IVB Colon Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: fluorouracil
Drug: leucovorin calcium
Drug: oxaliplatin
Biological: bevacizumab

First Posted Date: 2003-05-07

Last Posted Date: 2013-09-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 24

Registration Number: NCT00060411

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy